This report aims to provide a comprehensive presentation of the global market for Castration-resistant Prostate Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Castration-resistant Prostate Cancer Drugs. This report contains market size and forecasts of Castration-resistant Prostate Cancer Drugs in global, including the following market information:
- Global Castration-resistant Prostate Cancer Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
- Global top five companies in 2022 (%)
The global Castration-resistant Prostate Cancer Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Oral Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Castration-resistant Prostate Cancer Drugs include Pfizer, Astellas, Janssen, AstraZeneca, Bayer, Hengrui, CTTQ, Sanofi and Hansoh, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Castration-resistant Prostate Cancer Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Castration-resistant Prostate Cancer Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, by Type, 2022 (%)
- Oral
- Intravenous Injection
- Others
Global Castration-resistant Prostate Cancer Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, by Application, 2022 (%)
- Hospital
- Specialty Clinic
- Others
Global Castration-resistant Prostate Cancer Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Castration-resistant Prostate Cancer Drugs Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Castration-resistant Prostate Cancer Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Castration-resistant Prostate Cancer Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- Pfizer
- Astellas
- Janssen
- AstraZeneca
- Bayer
- Hengrui
- CTTQ
- Sanofi
- Hansoh
- Clovis Oncology
- Zhendong Pharmaceutical
- Merck
Outline of Major Chapters:
- Chapter 1: Introduces the definition of Castration-resistant Prostate Cancer Drugs, market overview.
- Chapter 2: Global Castration-resistant Prostate Cancer Drugs market size in revenue.
- Chapter 3: Detailed analysis of Castration-resistant Prostate Cancer Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
- Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
- Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
- Chapter 6: Sales of Castration-resistant Prostate Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
- Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
- Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Castration-resistant Prostate Cancer Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Castration-resistant Prostate Cancer Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Castration-resistant Prostate Cancer Drugs Overall Market Size
2.1 Global Castration-resistant Prostate Cancer Drugs Market Size: 2022 VS 2029
2.2 Global Castration-resistant Prostate Cancer Drugs Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Castration-resistant Prostate Cancer Drugs Players in Global Market
3.2 Top Global Castration-resistant Prostate Cancer Drugs Companies Ranked by Revenue
3.3 Global Castration-resistant Prostate Cancer Drugs Revenue by Companies
3.4 Top 3 and Top 5 Castration-resistant Prostate Cancer Drugs Companies in Global Market, by Revenue in 2022
3.5 Global Companies Castration-resistant Prostate Cancer Drugs Product Type
3.6 Tier 1, Tier 2 and Tier 3 Castration-resistant Prostate Cancer Drugs Players in Global Market
3.6.1 List of Global Tier 1 Castration-resistant Prostate Cancer Drugs Companies
3.6.2 List of Global Tier 2 and Tier 3 Castration-resistant Prostate Cancer Drugs Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Castration-resistant Prostate Cancer Drugs Market Size Markets, 2022 & 2029
4.1.2 Oral
4.1.3 Intravenous Injection
4.1.4 Others
4.2 By Type - Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
4.2.1 By Type - Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
4.2.2 By Type - Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
4.2.3 By Type - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Castration-resistant Prostate Cancer Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Specialty Clinic
5.1.4 Others
5.2 By Application - Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
5.2.1 By Application - Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
5.2.2 By Application - Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
5.2.3 By Application - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region - Global Castration-resistant Prostate Cancer Drugs Market Size, 2022 & 2029
6.2 By Region - Global Castration-resistant Prostate Cancer Drugs Revenue & Forecasts
6.2.1 By Region - Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2023
6.2.2 By Region - Global Castration-resistant Prostate Cancer Drugs Revenue, 2024-2029
6.2.3 By Region - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country - North America Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.3.2 US Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.3.3 Canada Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.3.4 Mexico Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4 Europe
6.4.1 By Country - Europe Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.4.2 Germany Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.3 France Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.4 U.K. Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.5 Italy Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.6 Russia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.7 Nordic Countries Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.4.8 Benelux Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5 Asia
6.5.1 By Region - Asia Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.5.2 China Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.3 Japan Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.4 South Korea Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.5 Southeast Asia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.5.6 India Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.6 South America
6.6.1 By Country - South America Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.6.2 Brazil Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.6.3 Argentina Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029
6.7.2 Turkey Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.3 Israel Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.4 Saudi Arabia Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
6.7.5 UAE Castration-resistant Prostate Cancer Drugs Market Size, 2018-2029
7 Castration-resistant Prostate Cancer Drugs Companies Profiles
7.1 Pfizer
7.1.1 Pfizer Company Summary
7.1.2 Pfizer Business Overview
7.1.3 Pfizer Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.1.4 Pfizer Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.1.5 Pfizer Key News & Latest Developments
7.2 Astellas
7.2.1 Astellas Company Summary
7.2.2 Astellas Business Overview
7.2.3 Astellas Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.2.4 Astellas Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.2.5 Astellas Key News & Latest Developments
7.3 Janssen
7.3.1 Janssen Company Summary
7.3.2 Janssen Business Overview
7.3.3 Janssen Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.3.4 Janssen Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.3.5 Janssen Key News & Latest Developments
7.4 AstraZeneca
7.4.1 AstraZeneca Company Summary
7.4.2 AstraZeneca Business Overview
7.4.3 AstraZeneca Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.4.4 AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.4.5 AstraZeneca Key News & Latest Developments
7.5 Bayer
7.5.1 Bayer Company Summary
7.5.2 Bayer Business Overview
7.5.3 Bayer Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.5.4 Bayer Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.5.5 Bayer Key News & Latest Developments
7.6 Hengrui
7.6.1 Hengrui Company Summary
7.6.2 Hengrui Business Overview
7.6.3 Hengrui Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.6.4 Hengrui Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.6.5 Hengrui Key News & Latest Developments
7.7 CTTQ
7.7.1 CTTQ Company Summary
7.7.2 CTTQ Business Overview
7.7.3 CTTQ Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.7.4 CTTQ Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.7.5 CTTQ Key News & Latest Developments
7.8 Sanofi
7.8.1 Sanofi Company Summary
7.8.2 Sanofi Business Overview
7.8.3 Sanofi Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.8.4 Sanofi Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.8.5 Sanofi Key News & Latest Developments
7.9 Hansoh
7.9.1 Hansoh Company Summary
7.9.2 Hansoh Business Overview
7.9.3 Hansoh Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.9.4 Hansoh Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.9.5 Hansoh Key News & Latest Developments
7.10 Clovis Oncology
7.10.1 Clovis Oncology Company Summary
7.10.2 Clovis Oncology Business Overview
7.10.3 Clovis Oncology Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.10.4 Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.10.5 Clovis Oncology Key News & Latest Developments
7.11 Zhendong Pharmaceutical
7.11.1 Zhendong Pharmaceutical Company Summary
7.11.2 Zhendong Pharmaceutical Business Overview
7.11.3 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.11.4 Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.11.5 Zhendong Pharmaceutical Key News & Latest Developments
7.12 Merck
7.12.1 Merck Company Summary
7.12.2 Merck Business Overview
7.12.3 Merck Castration-resistant Prostate Cancer Drugs Major Product Offerings
7.12.4 Merck Castration-resistant Prostate Cancer Drugs Revenue in Global Market (2018-2023)
7.12.5 Merck Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Castration-resistant Prostate Cancer Drugs Market Opportunities & Trends in Global Market
Table 2. Castration-resistant Prostate Cancer Drugs Market Drivers in Global Market
Table 3. Castration-resistant Prostate Cancer Drugs Market Restraints in Global Market
Table 4. Key Players of Castration-resistant Prostate Cancer Drugs in Global Market
Table 5. Top Castration-resistant Prostate Cancer Drugs Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Castration-resistant Prostate Cancer Drugs Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Castration-resistant Prostate Cancer Drugs Revenue Share by Companies, 2018-2023
Table 8. Global Companies Castration-resistant Prostate Cancer Drugs Product Type
Table 9. List of Global Tier 1 Castration-resistant Prostate Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Castration-resistant Prostate Cancer Drugs Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Castration-resistant Prostate Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Castration-resistant Prostate Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application ? Global Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Castration-resistant Prostate Cancer Drugs Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Castration-resistant Prostate Cancer Drugs Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region ? Global Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2024-2029
Table 30. Pfizer Company Summary
Table 31. Pfizer Castration-resistant Prostate Cancer Drugs Product Offerings
Table 32. Pfizer Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 33. Pfizer Key News & Latest Developments
Table 34. Astellas Company Summary
Table 35. Astellas Castration-resistant Prostate Cancer Drugs Product Offerings
Table 36. Astellas Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 37. Astellas Key News & Latest Developments
Table 38. Janssen Company Summary
Table 39. Janssen Castration-resistant Prostate Cancer Drugs Product Offerings
Table 40. Janssen Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 41. Janssen Key News & Latest Developments
Table 42. AstraZeneca Company Summary
Table 43. AstraZeneca Castration-resistant Prostate Cancer Drugs Product Offerings
Table 44. AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 45. AstraZeneca Key News & Latest Developments
Table 46. Bayer Company Summary
Table 47. Bayer Castration-resistant Prostate Cancer Drugs Product Offerings
Table 48. Bayer Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 49. Bayer Key News & Latest Developments
Table 50. Hengrui Company Summary
Table 51. Hengrui Castration-resistant Prostate Cancer Drugs Product Offerings
Table 52. Hengrui Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 53. Hengrui Key News & Latest Developments
Table 54. CTTQ Company Summary
Table 55. CTTQ Castration-resistant Prostate Cancer Drugs Product Offerings
Table 56. CTTQ Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 57. CTTQ Key News & Latest Developments
Table 58. Sanofi Company Summary
Table 59. Sanofi Castration-resistant Prostate Cancer Drugs Product Offerings
Table 60. Sanofi Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 61. Sanofi Key News & Latest Developments
Table 62. Hansoh Company Summary
Table 63. Hansoh Castration-resistant Prostate Cancer Drugs Product Offerings
Table 64. Hansoh Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 65. Hansoh Key News & Latest Developments
Table 66. Clovis Oncology Company Summary
Table 67. Clovis Oncology Castration-resistant Prostate Cancer Drugs Product Offerings
Table 68. Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 69. Clovis Oncology Key News & Latest Developments
Table 70. Zhendong Pharmaceutical Company Summary
Table 71. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Product Offerings
Table 72. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 73. Zhendong Pharmaceutical Key News & Latest Developments
Table 74. Merck Company Summary
Table 75. Merck Castration-resistant Prostate Cancer Drugs Product Offerings
Table 76. Merck Castration-resistant Prostate Cancer Drugs Revenue (US$, Mn) & (2018-2023)
Table 77. Merck Key News & Latest Developments
List of Figures
Figure 1. Castration-resistant Prostate Cancer Drugs Segment by Type in 2022
Figure 2. Castration-resistant Prostate Cancer Drugs Segment by Application in 2022
Figure 3. Global Castration-resistant Prostate Cancer Drugs Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Castration-resistant Prostate Cancer Drugs Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Castration-resistant Prostate Cancer Drugs Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Castration-resistant Prostate Cancer Drugs Revenue in 2022
Figure 8. By Type - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 9. By Application - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 10. By Type - Global Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 12. By Application - Global Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 14. By Region - Global Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 15. By Country - North America Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 16. US Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 20. Germany Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 21. France Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 28. China Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 32. India Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 34. Brazil Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Castration-resistant Prostate Cancer Drugs Revenue Market Share, 2018-2029
Figure 37. Turkey Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Castration-resistant Prostate Cancer Drugs Revenue, (US$, Mn), 2018-2029
Figure 41. Pfizer Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Astellas Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Janssen Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AstraZeneca Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Bayer Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Hengrui Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. CTTQ Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Sanofi Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Hansoh Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Clovis Oncology Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Zhendong Pharmaceutical Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Merck Castration-resistant Prostate Cancer Drugs Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
